Crossover hits Compass
The Companion-002 trial of tovecimig fails to show an overall survival benefit versus chemo.
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
Compass claims a pivotal win with tovecimig
A biliary tract cancer trial hits on response rate, but survival data will be key.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Relay passes on the lirafugratinib baton
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
